Merck said the acquisition of Sigma-Aldrich,apart from the expected organic growth of net sales, will have a positive impact on the operating result before exceptionals (EBITDA pre) in coming year. This includes expected cost synergies of 90 million euros. Merck said it is planning additional investments of around 250 million euros in its pharmaceutical pipeline. In November, the company had forecast EBITDA pre of between 3.58 billion euros and 3.65 billion euros for 2015.
